Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...